Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease

As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the developme...

Descripción completa

Detalles Bibliográficos
Autores principales: Lobello, Kasia, Ryan, J. Michael, Liu, Enchi, Rippon, Gregory, Black, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265072/
https://www.ncbi.nlm.nih.gov/pubmed/22292124
http://dx.doi.org/10.1155/2012/628070
_version_ 1782222033878253568
author Lobello, Kasia
Ryan, J. Michael
Liu, Enchi
Rippon, Gregory
Black, Ronald
author_facet Lobello, Kasia
Ryan, J. Michael
Liu, Enchi
Rippon, Gregory
Black, Ronald
author_sort Lobello, Kasia
collection PubMed
description As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the development of various immunotherapeutic approaches targeting beta amyloid. This paper reviews active and passive approaches aimed at beta amyloid, with a focus on clinical trial data.
format Online
Article
Text
id pubmed-3265072
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32650722012-01-30 Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease Lobello, Kasia Ryan, J. Michael Liu, Enchi Rippon, Gregory Black, Ronald Int J Alzheimers Dis Review Article As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the development of various immunotherapeutic approaches targeting beta amyloid. This paper reviews active and passive approaches aimed at beta amyloid, with a focus on clinical trial data. Hindawi Publishing Corporation 2012 2012-01-15 /pmc/articles/PMC3265072/ /pubmed/22292124 http://dx.doi.org/10.1155/2012/628070 Text en Copyright © 2012 Kasia Lobello et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Lobello, Kasia
Ryan, J. Michael
Liu, Enchi
Rippon, Gregory
Black, Ronald
Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
title Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
title_full Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
title_fullStr Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
title_full_unstemmed Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
title_short Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
title_sort targeting beta amyloid: a clinical review of immunotherapeutic approaches in alzheimer's disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265072/
https://www.ncbi.nlm.nih.gov/pubmed/22292124
http://dx.doi.org/10.1155/2012/628070
work_keys_str_mv AT lobellokasia targetingbetaamyloidaclinicalreviewofimmunotherapeuticapproachesinalzheimersdisease
AT ryanjmichael targetingbetaamyloidaclinicalreviewofimmunotherapeuticapproachesinalzheimersdisease
AT liuenchi targetingbetaamyloidaclinicalreviewofimmunotherapeuticapproachesinalzheimersdisease
AT rippongregory targetingbetaamyloidaclinicalreviewofimmunotherapeuticapproachesinalzheimersdisease
AT blackronald targetingbetaamyloidaclinicalreviewofimmunotherapeuticapproachesinalzheimersdisease

Ejemplares similares